117 related articles for article (PubMed ID: 16220075)
1. Troglitazone inhibits long-term glycation and oxidation of low-density lipoprotein.
Sobal G; Menzel EJ; Sinzinger H
J Cardiovasc Pharmacol; 2005 Nov; 46(5):672-80. PubMed ID: 16220075
[TBL] [Abstract][Full Text] [Related]
2. Troglitazone-binding to LDL and its glycated modifications: its role in cell-catalysed and Cu-mediated LDL-oxidation.
Sobal G; Sinzinger H; Menzel EJ
Life Sci; 2000 Jun; 67(6):695-707. PubMed ID: 12659175
[TBL] [Abstract][Full Text] [Related]
3. The role of antioxidants in the long-term glycation of low density lipoprotein and its Cu2+-catalyzed oxidation.
Sobal G; Menzel J
Free Radic Res; 2000 May; 32(5):439-49. PubMed ID: 10766412
[TBL] [Abstract][Full Text] [Related]
4. The effects of glycation/glycoxidation on the liberation of 8-epi-PGF2alpha from low density lipoprotein during its in vitro oxidation.
Sobal G; Menzel EJ; Sinzinger H
Prostaglandins Leukot Essent Fatty Acids; 2000 Apr; 62(4):217-24. PubMed ID: 10882185
[TBL] [Abstract][Full Text] [Related]
5. Effects of troglitazone on in vitro oxidation of LDL and HDL induced by copper ions and endothelial cells.
Cominacini L; Garbin U; Pastorino AM; Campagnola M; Fratta Pasini A; Davoli A; Rigoni A; Lo Cascio V
Diabetologia; 1997 Feb; 40(2):165-72. PubMed ID: 9049476
[TBL] [Abstract][Full Text] [Related]
6. Troglitazone increases the resistance of low density lipoprotein to oxidation in healthy volunteers.
Cominacini L; Young MM; Capriati A; Garbin U; Fratta Pasini A; Campagnola M; Davoli A; Rigoni A; Contessi GB; Lo Cascio V
Diabetologia; 1997 Oct; 40(10):1211-8. PubMed ID: 9349604
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of oxidation of low density lipoprotein by troglitazone.
Noguchi N; Sakai H; Kato Y; Tsuchiya J; Yamamoto Y; Niki E; Horikoshi H; Kodama T
Atherosclerosis; 1996 Jun; 123(1-2):227-34. PubMed ID: 8782853
[TBL] [Abstract][Full Text] [Related]
8. Calcium antagonists as inhibitors of in vitro low density lipoprotein oxidation and glycation.
Sobal G; Menzel EJ; Sinzinger H
Biochem Pharmacol; 2001 Feb; 61(3):373-9. PubMed ID: 11172743
[TBL] [Abstract][Full Text] [Related]
9. Troglitazone inhibits oxidized low-density lipoprotein-induced macrophage proliferation: impact of the suppression of nuclear translocation of ERK1/2.
Yano M; Matsumura T; Senokuchi T; Ishii N; Motoshima H; Taguchi T; Matsuo T; Sonoda K; Kukidome D; Sakai M; Kawada T; Nishikawa T; Araki E
Atherosclerosis; 2007 Mar; 191(1):22-32. PubMed ID: 16725145
[TBL] [Abstract][Full Text] [Related]
10. Effects of PGI2 and analogues (taprostene, iloprost) on oxidation of native and glycated LDL.
Sobal G; Sinzinger H
Life Sci; 1999; 65(12):1237-46. PubMed ID: 10503939
[TBL] [Abstract][Full Text] [Related]
11. Effect of simvastatin on the oxidation of native and modified lipoproteins.
Sobal G; Sinzinger H
Biochem Pharmacol; 2005 Oct; 70(8):1185-91. PubMed ID: 16143314
[TBL] [Abstract][Full Text] [Related]
12. Troglitazone, an antidiabetic agent, inhibits cholesterol biosynthesis through a mechanism independent of peroxisome proliferator-activated receptor-gamma.
Wang M; Wise SC; Leff T; Su TZ
Diabetes; 1999 Feb; 48(2):254-60. PubMed ID: 10334298
[TBL] [Abstract][Full Text] [Related]
13. Troglitazone reduces LDL oxidation and lowers plasma E-selectin concentration in NIDDM patients.
Cominacini L; Garbin U; Fratta Pasini A; Campagnola M; Davoli A; Foot E; Sighieri G; Sironi AM; Lo Cascio V; Ferrannini E
Diabetes; 1998 Jan; 47(1):130-3. PubMed ID: 9421387
[TBL] [Abstract][Full Text] [Related]
14. The new oral hypoglycemic agent, CS-045, inhibits the lipid peroxidation of human plasma low density lipoprotein in vitro.
Nagasaka Y; Kaku K; Nakamura K; Kaneko T
Biochem Pharmacol; 1995 Sep; 50(7):1109-11. PubMed ID: 7575669
[TBL] [Abstract][Full Text] [Related]
15. Gliclazide decreases low-density lipoprotein oxidation and monocyte adhesion to the endothelium.
Renier G; Desfaits AC; Serri O
Metabolism; 2000 Feb; 49(2 Suppl 1):17-22. PubMed ID: 10693915
[TBL] [Abstract][Full Text] [Related]
16. Why is glycated LDL more sensitive to oxidation than native LDL? A comparative study.
Sobal G; Menzel J; Sinzinger H
Prostaglandins Leukot Essent Fatty Acids; 2000 Oct; 63(4):177-86. PubMed ID: 11049692
[TBL] [Abstract][Full Text] [Related]
17. Troglitazone inhibits fatty acid oxidation and esterification, and gluconeogenesis in isolated hepatocytes from starved rats.
Fulgencio JP; Kohl C; Girard J; Pégorier JP
Diabetes; 1996 Nov; 45(11):1556-62. PubMed ID: 8866561
[TBL] [Abstract][Full Text] [Related]
18. Troglitazone-induced changes in adiponectin do not affect endothelial function in diabetes.
Buras J; Reenstra WR; Orlow D; Horton ES; Veves A
Obes Res; 2005 Jul; 13(7):1167-74. PubMed ID: 16076985
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of LDL oxidation in vitro but not ex vivo by troglitazone.
Crawford RS; Mudaliar SR; Henry RR; Chait A
Diabetes; 1999 Apr; 48(4):783-90. PubMed ID: 10102695
[TBL] [Abstract][Full Text] [Related]
20. Tumor necrosis factor-alpha and troglitazone regulate plasminogen activator inhibitor type 1 production through extracellular signal-regulated kinase- and nuclear factor-kappaB-dependent pathways in cultured human umbilical vein endothelial cells.
Hamaguchi E; Takamura T; Shimizu A; Nagai Y
J Pharmacol Exp Ther; 2003 Dec; 307(3):987-94. PubMed ID: 14534369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
